Polypeptides and antibodies

Abstract

Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

1 - 113 . (canceled) 
     
     
         114 . A method of treating cancer in a patient that has cancer associated with tissue expressing TRAIL receptor-2 (TR-2) comprising administering to the patient a therapeutically effective amount of an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1 of SEQ ID NO: 30, CDR2 of SEQ ID NO: 30, and CDR3 of SEQ ID NO: 30, and wherein the light chain comprises CDR1 of SEQ ID NO: 64, CDR2 of SEQ ID NO: 64, and CDR3 of SEQ ID NO: 64, and wherein the antibody binds TR-2 and induces cancer cell apoptosis. 
     
     
         115 . The method of  claim 114 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 30, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 64. 
     
     
         116 . The method of  claim 114 , wherein the antibody is a fully human antibody. 
     
     
         117 . The method of  claim 115 , wherein the antibody is a fully human antibody. 
     
     
         118 . The method of  claim 114 , wherein the light chain comprises the amino acid sequence of SEQ ID NO: 64. 
     
     
         119 . The method of  claim 118 , wherein the antibody is a fully human antibody. 
     
     
         120 . The method of  claim 114 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 30 in which one of the cysteine residues of SEQ ID NO: 30 is replaced by one non-cysteine residue. 
     
     
         121 . The method of  claim 120 , wherein the antibody is a fully human antibody. 
     
     
         122 . The method of  claim 120 , wherein the light chain comprises the amino acid sequence of SEQ ID NO: 64. 
     
     
         123 . The method of  claim 122 , wherein the antibody is a fully human antibody.